Relatively low expression of IL-17 may explain the lack of neutrophils in lesions of CTCL, which correlates with bacterial infections that commonly occur in skin affected by CTCL.
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Translational relevance
T helper cells were classically divided into two groups, termed T H 1 and T H 2 cells. Recent studies have shown that there are other distinctive subsets, such as regulatory T cells, T H 17 cells, and T H 22 cells, which are associated with various human diseases. Targeting these subsets, cytokine blocking biologics have been applied or developed in human autoimmune disorders. Cutaneous T cell lymphoma was regarded as T H 2-dominant disease, whereas the roles of T H 17 and T H 22 cells in this disease were not well understood. In this study, we show IL-22 and CCL20, but not IL-17, expression is elevated in both sera and lesional skin in patients with cutaneous T cell lymphoma. We also detected abundant CCR6 + cells in lesional skin. Our results suggest that IL-22 may be important in cutaneous T cell lymphoma, which may prove to be a future therapeutic target. prolonged clinical course and only limited cases progress over years through patch, plaque, and tumor stages, followed by lymph node and visceral involvement (1) . SS is characterized by fever, erythroderma, lymphadenopathy, and leukemic involvement, and usually has a rapid clinical course (2) . Clinical appearances of CTCL, represented by pruritic erythematous patches and plaques frequently accompanied with bacterial infection, are quite similar to those observed in individuals with atopic dermatitis (AD). Laboratory findings can also be similar in CTCL and AD, such as eosinophilia, high serum levels of lactate dehydrogenase (LDH), immunoglobulin E (IgE), and soluble interleukin-2 receptor (sIL-2R; ref. [3] [4] [5] . Histologic appearance is the key to distinguish between these two diseases. CTCL is characterized by epidermotropism of atypical lymphoid cells, which is not seen in AD skin. However, in some cases of CTCL, especially with erythroderma, epidermotropism is not remarkable. Epidermal hyperplasia and dermal lymphocytic infiltration are common findings. Therefore, the clinical and histologic differential diagnosis between CTCL and AD is sometimes very difficult. In addition, cases with CTCL proceeded by AD have been reported (6, 7) . We have reported that both CTCL and AD patients show elevated serum levels of CC chemokine ligand (CCL) 17, CCL27, CCL11, and CCL26, which may help explain some of the similar clinical, laboratory, and histologic features of these two diseases (8) (9) (10) (11) (12) .
T H 17 cells are characterized by production of interleukin (IL)-17A in the absence of IFN-γ (13, 14) . T H 17 cells produce IL-17A, IL-17F, tumor necrosis factor-alpha (TNF-α), IL-6, and IL-22.
Research. (22) (23) (24) (25) (26) (27) (28) . Among cytokines produced by T H 17 cells, IL-22 is regarded as important in skin diseases characterized by epidermal hyperplasia (29) .
IL-22 acts on keratinocytes, inducing their proliferation through phosphorylation of signal transducer and activator of transcription (STAT) 3. Although IL-22 production was initially linked with IL-17A expression in Th17 cells, recent evidence shows that a unique T helper cell subset, T H 22 cells, produce IL-22, IL-10, and TNF-α in the absence of IL-17A (30, 31) . It was recently demonstrated that IL-22-expressing T cells are increased in the lesional skin of AD patients (26) . Thus, IL-22 is presumed to play important roles in the pathogenesis of various skin diseases. In this study, we assessed the role of IL-22, IL-17, and their corresponding signature cytokines in CTCL, using psoriasis as a positive control.
Materials and Methods
Tissue and serum samples
Messenger RNA (mRNA) was obtained from biopsy materials of lesional skin of CTCL (n = 21, 6 cases with patch MF, 5 cases with plaque MF, 6 cases with tumor MF, 1 case with erythrodermic MF, 3cases with SS) and psoriasis (n = 5), and in normal skin adjacent to benign skin tumors (n = 6) using Illustra QuickPrep Micro mRNA Purification Kit (GE Healthcare, Buckinghamshire, UK). Skin samples for immunohistochemistry were collected from CTCL patients (n = 12, 1 case with patch MF, 5 cases with plaque MF, 3 cases with tumor MF, 1 case 
Enzyme-linked immunosorbent assay (ELISA)
Immunoreactive IL-22, IL-17A, IL-10, and CCL20 in sera were quantified using human ELISA kits (R&D systems. Minneapolis, MN, USA). These assays employ the quantitative sandwich enzyme immunoassay technique. Optical densities were measured at 450 nm using a Bio-Rad Model 550 microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). The concentrations were calculated from the standard curve generated by a curve-fitting program.
The measured values from individual patients were plotted by dots. 
Statistical analysis
Statistical analysis between two groups was performed using the Mann-Whitney's U-test.
Correlation coefficients were determined by using the Spearman's rank correlation test. P-values of < 0.05 were considered statistically significant.
Results
Increased mRNA expression of IL-22, IL-10, IL-4, CCL20, and CCR6, but not IL-17A, IL-17F, IL-23p19, IL-8, or IL-20, in CTCL skin
To investigate IL-22/IL-17 involvement in CTCL, we first examined mRNA expression of IL-22, IL-17A, IL-17F, and IL-23p19 in lesional skin of CTCL and psoriasis, and normal skin.
Expression levels of IL-22 mRNA were markedly elevated in CTCL skin, especially in advanced cases (P < 0.01; Fig. 1A ). IL-22 mRNA expression was also significantly increased in psoriatic skin (P < 0.01). Expression of IL-17A and IL-23p19 mRNA was slightly increased in a few cases of CTCL. Expression of IL-17F mRNA was not detected in CTCL. On the other hand, mRNA expression of these cytokines was significantly up-regulated in the lesional skin of psoriasis (P < 0.01, P < 0.05, and P < 0.01, respectively), which was consistent with previous reports (17, 19, 23) . We also examined expression of IL-10 and IL-4, major T H 2 cytokines. IL-10 and IL-4 mRNA expression was increased in advanced CTCL as expected (P < 0.05), but not in psoriatic skin (Fig. 1A) . We next investigated mRNA expression of downstream molecules induced by IL- CCL20 mRNA expression was increased in both advanced CTCL and psoriatic skin (P < 0.05, and P < 0.05, respectively; Fig. 1A ). CCR6, a sole receptor for CCL20, was also up-regulated in the lesional skin of these diseases (P < 0.05, and P < 0.05, respectively). IL-22 and IL-17 synergistically stimulate keratinocytes to produce IL-8 and IL-20, while IL-22 alone has little effect (23, 32, 33) . Consistent with this, IL-8 and IL-20 mRNA expression was increased only in psoriatic skin (P < 0.01, and P < 0.05, respectively), but not in CTCL skin (Fig. 1A and data now shown). Thus, mRNA expression of IL-22, IL-10, IL-4, CCL20, and CCR6, but not IL-17, IL23p19, IL-8, or IL-20, was significantly increased in CTCL skin.
IL-22, CCL20, and CCR6 mRNA expression levels in CTCL skin correlate with one another
When mRNA expression levels of all 32 samples, including normal, CTCL, and psoriatic skin, were examined, there were significant correlations between IL-22 and CCL20, CCL20 and CCR6, and IL-22 and CCR6 (r = 0.54, P < 0.01, r = 0.51, P < 0.01, and r = 0.55, P < 0.01, respectively). Interestingly, there were also significant correlations between IL-17A and IL-17F, IL-23p19 and IL-17A, and IL-23p19 and IL-17F (r = 0.61, P < 0.01, r = 0.30, P < 0.05, and r = 0.53, P < 0.01, respectively). IL-17A and IL-17F levels correlated with IL-8 levels (r = 0.28, P < 0.05, and r = 0.60, P < 0.01, respectively). IL-17F levels also correlated with IL-20 levels (r = 0.62, P < 0.01). These results were consistent with previous reports that IL-22 induced expression of CCL20, a ligand for CCR6, and that IL-23p19 was important for maintaining T H 17 cells, which induced keratinocytes to express IL-8 and IL-20 (17, 20, 23, 32, 33 
expression levels with each other. IL-22 mRNA levels significantly correlated with CCL20 and CCR6 mRNA levels (r = 0.54, P < 0.05, and r = 0.50, P < 0.05, respectively; Fig. 1B ). CCL20 mRNA levels also significantly correlated with CCR6 mRNA levels (r = 0.38, P < 0.0). Thus, IL-22, CCL20, and CCR6 mRNA expression levels in CTCL skin correlated with one another.
IL-22, CCL20, CCR6, and pSTAT3, but not IL-17A, are expressed in lesional skin of CTCL We next immunolabeled lesional skin of CTCL and psoriasis as well as normal skin for IL-22, IL-17A, CCL20, and CCR6. Consistent with the above results, CTCL, especially in advanced cases, and psoriatic skin contained many IL-22-expressing cells in the dermis (Fig. 2A) . No infiltrating cells expressed IL-17A in CTCL skin, whereas IL-17-expressing cells were scattered in the upper dermis of psoriatic skin (Fig. 2B) . Abundant CCL20 expression in epidermal keratinocytes and dermal CCR6 + cells, some of which showed dendritic morphology, was detected in both diseases ( Fig. 2C and D) . We also examined phosphorylation of STAT3, which CCL20 was reported to mediate. As expected, nuclear staining of pSTAT3 was detected in epidermal keratinocytes and dermal infiltrating lymphocytes in CTCL and psoriatic skin ( 
Elevated serum levels of IL-22, IL-10, and CCL20 in patients with CTCL
We next measured serum IL-22, IL-17A, IL-10, and CCL20 levels in patients with CTCL and healthy controls. Serum IL-22 levels in CTCL patients were 40.1 ± 50.4 pg/ml, which were 13 significantly higher than healthy controls (14.1 ± 3.2 pg/ml; P < 0.01) and almost same as those in psoriasis patients described in the previous report (31) . Both serum IL-22 levels in patients with early CTCL and those with advanced CTCL were significantly higher than those of controls (22.5 ± 17.9 pg/ml, P < 0.01 and 77.8 ± 83.9 pg/ml, P < 0.01, respectively; Fig. 3A ). In addition, the IL-22 levels of patients with advanced CTCL were significantly higher than those of patients with early CTCL (P < 0.01). Serum IL-17A was under detection levels in all samples (data not shown). Serum IL-10 levels of patients with CTCL were 11.9 ± 3.3 pg/ml, which were significantly higher than healthy controls (9.9 ± 1.9 pg/ml; P < 0.05). Serum IL-10 levels in patients with advanced CTCL (14.1 ± 3.4 pg/ml), but not those with early CTCL (10.5 ± 2.5 pg/ml), were significantly higher than those of controls (P < 0.01; Fig. 3B ). Serum CCL20 levels of patients with CTCL were 169.1 ± 440.5 pg/ml, which were significantly higher than healthy controls (12.5 ± 10.9 pg/ml; P < 0.01). Both serum CCL20 levels in patients with early CTCL and those with advanced CTCL were significantly higher than those of controls (32.8 ± 22.9 pg/ml, P < 0.01 and 422.3 ± 409.2 pg/ml, P < 0.01, respectively; Fig. 3C ). Thus, serum IL-22, IL-10, and CCL20 levels were elevated in patients with CTCL.
Serum IL-22 levels correlate with serum LDH, sIL-2R, and CCL27 levels in patients with
CTCL
We next compared serum IL-22 and CCL20 levels with other clinical and laboratory data: age, sex, serum levels of LDH, IgE, sIL-2R, CCL17, CCL27, and numbers of eosinophils in peripheral blood. Serum IL-22 levels correlated with serum LDH, sIL-2R, and CCL27 levels, all of which were reported to be disease severity markers of CTCL (r = 0.32, P < 0.05, r = 0.35, P < 0.05, and r = 0.38, P < 0.05, respectively; Fig. 4A-C correlated with serum LDH levels (r = 0.30, P < 0.05; Fig. 4D ). Other factors were not correlated with serum IL-22 or CCL20 levels (data not shown). Thus, serum IL-22 levels in patients with CTCL significantly correlated with serum markers known to reflect disease severity, similar to reports in psoriasis (31) .
In peripheral blood of patients with SS, the malignant clonal T cells produce IL-17 rather than IL-22, while the remaining benign T cells produce IL-22 rather than IL-17
We next examined whether clonal malignant T cells or benign reactive T cells produce IL-22, using peripheral blood of three patients with SS and three healthy controls. IL-17 or IL-22-producing cells were a minor population of circulating peripheral blood cells (Fig 5A) .
Interestingly, frequencies of IL-17-producing cells were higher in malignant clonal T cells when compared to benign T cells (Fig. 5B) . By contrast, frequencies of IL-22-producing cells were high in the benign T cells, compared to the malignant clonal T cells. In healthy controls, frequencies of IL-17 or IL-22-producing cells were less than 0.5% (data not shown). Thus, tumor cells in peripheral blood of CTCL do not produce IL-22, suggesting that the main source of IL-22, elevated in lesional skin and sera from patients with CTCL, is reactive benign T cells.
Discussion
In the present study, we showed that expression of IL-22, IL-10, IL-4, CCL20, and CCR6, but There have been few reports examining T H 22 and T H 17 cytokine profiles in CTCL patients. IL-17A mRNA expression was detected in the lesional skin of some CTCL cases, but not in all cases (27) . In another report, activated peripheral blood mononuclear cells from patients with CTCL without blood involvement showed increased IL-17A mRNA expression, while those from CTCL with blood involvement did not (28) . In our current study, IL-17A mRNA was elevated in CTCL skin in a few cases (Fig. 1A) , which is consistent with previous reports. In addition, a small population of malignant clonal T cells in peripheral blood from patients with SS produced IL-17 (Fig. 5) . The cutaneous microenvironment in CTCL may suppress IL-17 expression by tumor cells. For example, high expression of T H 2 cytokines, such as IL-10 and IL-4, may inhibit IL-17 production (34). IL-22 mRNA expression, on the other hand, was significantly increased in CTCL skin in most of patients (Fig. 1A) . Immunohistochemical analysis also showed abundant expression of IL-22 ( Fig. 2A and Table 1 ). We also showed significant increases in serum IL-22, IL-10, and CCL20 levels in patients with CTCL, especially in advanced cases (Fig. 3) . Serum IL-22 levels positively correlated with serum sIL-2R, LDH, and CCL27 levels, which are all reported to reflect disease activity in CTCL ( Fig. 4A-C; ref. 4, 5,   10 ). According to a previous report, IL-17A down-regulates CCL27 expression in keratinocytes, which are the main source of this chemokine (35) . The significant correlation between serum IL-22 and CCL27 levels in CTCL was consistent with the conclusion that IL-22, but not IL-17, is dominant in CTCL. Serum CCL20 levels were also significantly correlated with serum LDH levels (Fig. 4D) . Our results indicate that serum IL-22 and CCL20 levels are good markers of disease severity in CTCL.
Research. In CTCL, we hypothesize that IL-22 promotes CCL20 expression in keratinocytes and that CCL20, in turn, induces chemotaxis of CCR6 + cells, as has been proposed in psoriasis (16, 23) .
We showed that CCR6 mRNA expression was significantly increased in advanced CTCL (Fig.   1A ). CCR6 mRNA expression levels correlated with IL-22 and CCL20 mRNA expression levels (Fig. 1B) . By immunohistochemistry, we also detected abundant CCR6 + cells in the dermis of CTCL skin (Fig. 2D and Table 1 Foxp3, also express CCR6. We found that Foxp3 mRNA expression levels were not increased in lesional skin of CTCL (data not shown), which was consistent with a previous report (43) . In another report, however, the relative amount of Tregs in peripheral blood was higher in CTCL compared to healthy controls (44) . In another study, dysfunction of peripheral Tregs in certain CTCL patients was reported, although the frequency of Tregs did not differ significantly between patients and controls (45) . Therefore, it is possible that CCL20 affects the function of Tregs, helping establish a tumor environment advantageous for proliferation and survival of tumor cells as has been proposed in Hodgkin's lymphoma (46) .
We detected CCL20 mRNA and protein expression in CTCL and psoriatic skin (Fig. 1A and   2C ). Phosphorylation of STAT3, the principal mediator of IL-22 signaling (29) , was also detected in epidermal keratinocytes and dermal infiltrating cells in CTCL skin as well as psoriatic skin (Fig. 2E) . It has been reported that IL-22 in psoriatic skin induces epidermal hyperplasia, which is mainly dependent on CCL20 expression and STAT3 phosphorylation (18, 23, 29) . Consistent with detection of pSTAT3 in keratinocytes, acanthosis is often seen in lesional skin of CTCL.
Increasing evidence suggests that IL-17A is a master regulator of antimicrobial peptides in keratinocytes, playing a central role in host defense against microorganisms at mucocutaneous surfaces of the body (47, 48) . Relatively low IL-17 mRNA expression in CTCL skin compared with psoriatic skin may correlate with reduced expression of key antimicrobial peptides. Indeed, we found that IL-8 mRNA expression was significantly increased in psoriatic skin, but not in CTCL skin (Fig. 1A) . This finding was consistent with the previous report describing that IL-17A, but not IL-22, induces IL-8 production from keratinocytes (23) . Expression levels of IL-8, a strong chemotactic factor for neutrophils, may explain why neutrophils are detected in psoriasis, but only in rare cases of CTCL. In addition, T H 2 cytokines, such as IL-10 and IL-4, are reported to inhibit IL-17A-induced expression of antimicrobial proteins (25) . Based on our results and previous reports, CTCL and AD are polarized towards T H 2 with relatively low T H 17 activity, which might explain low innate defense molecules and frequent bacterial infection observed in these diseases (49, 50) .
In conclusion, our data suggest that IL-22 is important in the development of CTCL. Enhanced expression of CCL20 may explain epidermal hyperplasia and migration of CCR6 
